Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety.
Agnaldo Lopes da Silva FilhoGabriella Martins CarvalhoLarissa Cristelli de SenaLívia Passini Guimarães GomesMarcos Flávio Habib ValérioRaíssa Isabelle Leão MartinsEduardo Batista CândidoPublished in: Revista da Associacao Medica Brasileira (1992) (2020)
Women with mutations in the BRCA 1 and 2 genes are at increased risk for ovarian and breast cancer and therefore candidates for risk-reducing surgery, including salpingo-oophorectomy and mastectomy. Risk-reducing salpingo-oophorectomy (RRSO) is considered the most effective prophylactic measure for ovarian cancer prevention in this group of patients. This procedure involves loss of ovarian function and induced menopause. Estrogen therapy is the most effective treatment for controlling vasomotor symptoms and improving the quality of life of climacteric women. However, the potential hormonal stimulation of these tumors and the risk of breast cancer are a concern regarding the safety of hormone replacement therapy (HRT) in this population. This article aims to review the current evidence regarding the potential benefits and safety of HRT after RRSO.
Keyphrases
- breast cancer risk
- replacement therapy
- minimally invasive
- smoking cessation
- end stage renal disease
- polycystic ovary syndrome
- newly diagnosed
- human health
- stem cells
- type diabetes
- chronic kidney disease
- oxidative stress
- adipose tissue
- high glucose
- young adults
- cell therapy
- pregnant women
- mesenchymal stem cells
- acute coronary syndrome
- diabetic rats
- patient reported outcomes
- sleep quality
- estrogen receptor
- metabolic syndrome
- depressive symptoms
- percutaneous coronary intervention
- physical activity
- skeletal muscle